Recent News

Otsuka Pharmaceutical to Acquire Jnana Therapeutics

Boehringer Ingelheim secures novel immune checkpoint inhibitor with acquisition of Nerio Therapeutics

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

Avalon BioVentures Raises First Fund Dedicated to Early-Stage Biotech Investments